

Reference Number: FOIAH2324/274
From: Commercial
Date: 17 August 2023
Subject: Number of patients with Hereditary Angioedema (HAE) on the Dec 31st, 2022 and June 30th, 2023, and the volume of medication prescribed

Q1 The number of patients with **Hereditary Angioedema (HAE)** types 1, 2, normal C1 and Acquired HAE, on the Dec 31st, 2022 and June 30th, 2023, had the total number of patients each day requested.

A1 Information not held – no patients with Hereditary Angioedema (HAE) types 1, 2, normal C1 and Acquired HAE, on these specific days.

Q2 The volume of medication dispensed and/or consumed from **January 1st, 2023, to June 30th, 2023**, for each of the products below. If it is more convenient to specify the number of vials, pre-filled syringes, or tablets, that would also be very helpful.

List of Medications:

lanadelumab (Takzhyro)
pdC1-inhibitor (Cinryze and Berinert)
rC1-inhibitor (Ruconest)
icatibant (Firazyr and generic)
berotralstat (Orladeyo)

A2 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.